BenevolentAI, a British-based drug developer, is facing a boardroom coup led by its founder after seeing its shares slump since it floated little more than two years ago.
BenevolentAI is a leading, clinical-stage AI drug discovery company that combines advanced AI and machine learning with cutting edge science to discover and develop novel and more effective
Odyssey Announces Agreement to Combine with BenevolentAI tarantobuonasera.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tarantobuonasera.it Daily Mail and Mail on Sunday newspapers.